Given where we are on the start of the TAMARACK study now, and this combination. And with the idea that we would have the data from TAMARACK hopefully by the second half of 2024, we may be in a good position to have different options. If in fact, we have identified an appropriate vobra duo and lori combo dose going forward. So, one could imagine additional arms to that study to be included to ask that question would a combination be better than a single agent in such a setting. So, we’ll have to see, time will tell. We have more work to do on that. With regard to additional studies for lorigerlimab beyond the Phase 2 we just talked about, in combination with docetaxel, we think that there are different opportunities given the profile of the drug either late to very early stages of prostate cancer.
So, for instance, one might consider the hormone responsive setting moving further up the line. We want to get obviously this study going first in the post and then we’ll consider other opportunities in other lines of therapy going forward to lorigerlimab.
Etzer Darout: Great. Thank you. Congrats on the progress.
Scott Koenig: Thank you.
Operator: Thank you. Our next question comes from David Dai with SMBC. You may proceed.
David Dai: Great. Thanks for taking my questions. So, just one question on the vobra duo and lori combo trial, we did see quite a bit of Grade 3 treatment related toxicity of around 35% as you mentioned, Scott. So, how should we think about the safety profile of the combined trial? What are some additional, kind of adjustments on dosing you’re thinking about to reduce the safety ?
Scott Koenig: Yes. So, just to put this in context so that people are looking at apples-to-apples comparison, particularly with what you’re commenting on the lorigerlimab in terms of discontinuations and the AEs, remember that combinations for instance of ipilimumab and nivolumab will require a reduction to 1 mg per kg of ipilimumab to get a tolerable combination going forward and it’s limited to four doses of that combination within continued use of nivolumab in various clinical settings. So, I should point out that the patients being treated with lorigerlimab that had objective responses with the PSA90s I described to you have now been on the drug for over a year and they’re getting on a Q3 weekly basis. So, it was not surprising that over time you’re going to accumulate more side effects in aggregate in such a population and discontinuation rates, which are often much later than that would have occurred would say .
In fact, if you look at the CheckMate 650 study, if you look at the arm that got nivolumab 1 and ipi 3, the plan was to treat those patients with four doses on a Q6 basis of ipi and the mean number of doses in that arm of the study was 2. So again, tolerability was an issue there. Now, with regard to combining going forward, that’s why we’re doing the study right now is to see if new side effects occur, if you look at the actual side effect profile of the individual molecules, there’s very little overlap in terms of the type of side effects that we’re seeing by treatment of patients individually, but we’ll have to see as we go forward with regard to how we envision optimizing the dosing, well, quite often because the mechanisms by which these drugs work are quite different.
It may be that lower doses may be quite sufficient in combination to achieve the response rates that we hope to see that are better than the individual drugs alone.
David Dai: That’s very helpful. Thank you.
Operator: Thank you. Our next question comes from Jon Miller with Evercore ISI. You may proceed.
